Joanna Stacey, MD
Obstetrics & Gynecology · Temple, TXNPI 1093781569
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,100 of the $44,046 with a category attached, or 91.0%. Merck accounts for 67.6% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $22,928 and has fallen 81.5% since, to $4,244 in 2024. Among obstetrics & gynecology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 73 payments — averaging $603.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$30K
- Organon$14K
- Exeltis, USA Inc.$131
- Applied Medical Resources Corporation$96
- Abiomed$27
Across 2 payments — averaging $111,929 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$224K
What the payments were for
- Speaking & faculty fees$40,10091%
- Travel & lodging$2,9417%
- Food & beverage$1,0042%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 51 | $29,796 |
| Organon | 19 | $13,996 |
| Exeltis, USA Inc. | 1 | $131 |
| Applied Medical Resources Corporation | 1 | $96 |
| Abiomed | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$44,046 in reported general payments places this provider in the 95th percentile of 3,099 obstetrics & gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 21 | $1,165 |
| Norethindrone Acetate | 12 | $743 |
| Oxybutynin Chloride ErOxybutynin Chloride | 11 | $404 |
| Medroxyprogesterone Acetate | 11 | $308 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Temple
- Devin GarzaAustin$2M
- Shawn TassoneAustin$1.3M
- Dale StovallDallas$590K
- Karyn-Anne CumberbatchMissouri City$452K
- Robert AsgharianEl Paso$366K
- Catherine HansenWebster$357K
- Lisa JukesBee Cave$270K
- Susan CrockettLive Oak$269K
- Henry Garza IiiSan Antonio$258K
- Rene LunaMcAllen$257K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.